Anticardiolipin Antibody Assay: a Methodological Analysis for a better Consensus in Routine Determinations

Summary

Despite the widely recognized practical importance of anticardiolipin (aCL) ELISA, the reliability of this test has been recently discussed. In order to investigate this area on European scale, we sent to 30 experienced centers a questionnaire focusing on the diagnostic procedures applied to patients with antiphospholipid syndrome (APS) and on the detailed protocols used to perform aCL. Anticardiolipin ELISA was found to be the most frequently performed test in patients with suspected APS, but significant difference was shown among the various protocols. The cross-laboratory multiple examination of ten serum samples evaluated independently by the 24 centers pointed out the difficulty in getting comparable results. Therefore a “consensus” protocol was derived from the aCL methods giving the best performance. The materials and reagents necessary to perform the “consensus” method, including, as putative standards, one IgG and one IgM monoclonal antibody (HCAL and EY2C9) were distributed to 19 Centers. The results of one IgG and one IgM aCL high positive sera measured in serial dilutions were compared. A progressive decrease in the variability of the values obtained for a given sample appeared evident when all the laboratories used the same standard, in their own in-house ELISA and even more in the “consensus” ELISA.

Our data show that aCL ELISA standardization is necessary in order to obtain comparable results in different laboratories.

Keywords

Antiphospholipid syndrome - anticardiolipin antibodies - standardization

• References

• 1 Harris EN, Gharavi AE, Boey ML, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2: 1211-4.
• 2 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JCP, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
• 3 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
• 4 Triplett DA. Many faces of lupus anticoagulant. Lupus 1998; 7 S2 18-22.
• 5 Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: Report of a standardization workshop held in April 1986. Clin Exp Immunol 1987; 68: 215-22.
• 6 Harris EN, Gharavi AE, Patel SP, Hughes GRV. Anticardiolipin antibody testing. The need for standardization. Arthritis Rheum 1987; 30: 835-6.
• 7 Harris EN. The Second International Anti-Cardiolipin Standardization Workshop/The Kingstone Anti-Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990; 94: 476-84.
• 8 Harris EN, Pierangeli S, Birch D. Anticardiolipin Wet Workshop Report. Fifth International Symposium on Antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-24.
• 9 Kalden JR. WHO/IUIS Standardization Programme. Clin Exp Rheumatol 1992; 10 (Suppl. 05) 513-4.
• 10 Coulam CB, McIntyre JA, Wagenknecht D, Rote N. Interlaboratories inconsistencies in detection of anticardiolipin antibodies. Lancet 1990; 335 (suppl. 8693): 865.
• 11 Peaceman AM, Silver RK, Mac Gregor SN, Socol ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 166: 1780-7.
• 12 Reber G, Arvieux J, Comby E. Multicenter evaluation of nine kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995; 52: 444-52.
• 13 Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance program signals a cautious approach. Pathology 1999; 31 (Suppl. 02) 142-7.
• 14 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffat K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86 (10) 3685-91.
• 15 Ichikawa K, Tsutsumi A, Atsumi T, Matsuura E, Kobayashi S, Hughes GRV, Khamashta M, Koike T. A chimeric antibody with the human γ1 constant region as a putative standard for assays to detect IgG β-2-glycoprotein I antibodies. Arthritis Rheum 1999; 42: 2461-70.
• 16 Ichikawa K, Khamashta M, Koike T, Matsuura E, Hughes GRV. β-2-glyco-protein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453-61.
• 17 Nilsson IM, Astedt B, Hedner U. Intrauterine death and circulating anticoagulant “antithromboplastin”. Acta Med Scand 1975; 197: 153-9.
• 18 Bowie EJ, Thompson Jr JH, Pascuzzi Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-30.
• 19 Alarcon-Segovia D, Osmundson PJ. Peripheral vascular syndromes associated with systemic lupus erythematosus. Ann Intern Med 1965; 62: 416-30.
• 20 Alagille D, Crosnier J, Soulier JP. Anticoagulant circulant à activité anti-thromboplastique. Rev Franç et Clin Biol 1956; 1: 335-45.
• 21 Soulier JP, Boffa MC. Avortements à repetition, thromboses et anticoagulant circulant antithromboplastine. Nouv Presse Med 1980; 9: 859-64.
• 22 Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984; 56: 193-9.
• 23 Asherson RA, Khamashta MA, Ordi-Ros J. The “primary” antiphospholipid syndrome: Major clinical and serological features. Medicine 1989; 68: 366-74.
• 24 Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-4.
• 25 Roubey RAS. Antiphospholipid antibody syndrome. In: Arthritis and allied conditions: a textbook of rheumatology. Koopman WJ. (ed) Philadelphia: Lippincott, Williams & Wilkins; 1997: 1393-406.
• 26 Asherson RA, Cervera R. The Antiphospholipid Syndrome. In: Textbook of Rheumatology. Kelly WN, Ruddy S, Harris ED, Sledge CB. (eds). Philadelphia: WB Saunders Company; 1997: 1057-64.
• 27 Harris EN. Antiphospholipid Syndrome. In: Rheumatology. Klippel JH, Dieppe PA. (eds). London: Mosby; 1998. sect. 7, 35.1-6.
• 28 Tincani A, Spatola L, Cattaneo R, Balestrieri G. Antiphospholipid ELISA: The state of the art. Lupus 1996; 5: 477-9.
• 29 Tincani A, Brey R, Balestrieri G, Vitali C, Doria A, Galeazzi M, Meroni PL, Migliorini P, Neri R, Tavoni A, Bombardieri S. International survey on the management of patients with SLE. II. The result of a questionnaire regarding neuropsychiatric manifestations. Clin Exp Rheumatol 1996; 14 (Suppl. 16) 23-9.
• 30 Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146: 2153-6.
• 31 Tan EM, Smolen JS, McDougal JS, Butcher BT, Chonn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Roth-field NF, Smeenk R, Takasaki Y, van Venrooij WJ, Week A, Wilson M, Koziol JA. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. Arthritis Rheum 1999; 42: 455-64.